Clinical Trials Directory

Trials / Completed

CompletedNCT04836715

Prevalence of Visual Dysfunction in Neurological Disorders

Prevalence of Visual Dysfunction in Persons With Parkinson's Disease and Other Neurological Disorders

Status
Completed
Phase
Study type
Observational
Enrollment
92 (actual)
Sponsor
University of Florida · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

The objective is to determine the prevalence of visual dysfunction in People with Parkinson's Disease (PwP). The investigators will administer the: Visual Impairment in Parkinson's Disease Screen and Revised-Self-Report Assessment of Functional Visual Performance. Patients seen at Fixel Institute and their caregivers will be invited to participate. Responses to the 2 questionnaires will help determine prevalence rates of visual dysfunction in PwP compared to those both with and without other neurological conditions.

Detailed description

The purpose of this study is to identify the prevalence of visual dysfunction among Persons with Parkinson's Disease, compared to other neurological conditions and controls without neurological conditions. Data will be collected anonymously via RedCap. Patients seen at the Fixel Institute that have consented to be contacted regarding research opportunities will be recruited via blast email and advertisement in our Institute's monthly newsletter, the Movement Messenger. The email and newsletter will contain a link for participation in surveys within RedCap so the surveys can be completed anonymously at home. Participation will be completely voluntary and responses will be recorded anonymously. Data will include responses to the following: screening questions, the VIPDQ (Visual Impairment in PD Questionnaire), and the R-SRAFVP (Revised-Self-Report Assessment of Functional Visual Performance). The investigators will calculate the prevalence of visual impairment (from the VIPDQ) and dysfunction in performance of daily activities (from the R-SRAFVP) for PwP and compare this to the prevalence occurring in other neurological populations as well as the population without any neurological conditions. Other data are collected so the investigators can then evaluate potential confounds or covariates. To ensure statistical methods are accurate, a statistician will be consulted.

Conditions

Timeline

Start date
2021-01-10
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2021-04-08
Last updated
2024-06-12

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04836715. Inclusion in this directory is not an endorsement.